Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P69 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/EGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology - Basic and Translational Science
    • +

      P69.01 - Real-World Data of EGFR-TKI Treatment Sequence in Non-Small Cell Lung Cancer Patients in Japan

      00:00 - 00:00  |  Presenter: Kentarou Ito

      • Abstract

      Loading...

    • +

      P69.02 - Identification of Potential Core Gene in Immune Infiltrates of EGFR Mutant Lung Adenocarcinoma using Bioinformatics Analysis

      00:00 - 00:00  |  Presenter: Zhaoxia Wang

      • Abstract

      Loading...

    • +

      P69.03 - Targeting the STAT3/PIM Kinase Pathway to Overcome EMT-Mediated Acquired Resistance to EGFR TKIs in NSCLC

      00:00 - 00:00  |  Presenter: Kathy Gately

      • Abstract

      Loading...

    • +

      P69.04 - Reduction of Drug Resistance Through Calcium Control in EGFR TKI  Resistant Lung Cancer Cells

      00:00 - 00:00  |  Presenter: Sei-hoon Yang

      • Abstract

      Loading...

    • +

      P69.05 - Molecular and Cellular Heterogeneity Underpin Treatment Response Across a Spectrum of EGFR-Mutant Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Ju Yuan

      • Abstract

      Loading...

  • +

    P70 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/OTHERS

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology - Basic and Translational Science
    • +

      P70.01 - Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P70.02 - Clinicopathologic Characteristics and Outcomes of East Asian Patients With Non-Small-Cell Lung Cancer and FLT3 Mutations

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P70.03 - Molecular Characterization of AKT1 Gene in East Asian Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P70.04 - Outcomes of Molecular Characteristics in East Asian IDH2-mutant Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P70.05 - The Association Between MAP2K1 Mutation Class and Clinical Features in MAP2K1‑Mutant East Asian Non‑Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

  • +

    P71 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/VEGF

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology - Basic and Translational Science
    • +

      P71.01 - The Effects of Vascular Endothelial Cells on Regulating Post-Irradiation Microglia Phenotype in Irradiation-Induced Brain Injury        

      00:00 - 00:00  |  Presenter: Jiaojiao Wang

      • Abstract

      Loading...

    • +

      P71.02 - Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models

      00:00 - 00:00  |  Presenter: Sonia A Patel

      • Abstract

      Loading...

  • +

    P72 - Tumor Biology and Systems Biology - Basic and Translational Science - Tumor Microenvironment

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology - Basic and Translational Science
    • +

      P72.01 - Stress-Induced Upregulation of TNFSF4 in Cancer Associated Fibroblasts Facilitates Chemoresistance of Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Yan Li

      • Abstract

      Loading...

    • +

      P72.02 - Cellular Landscape of Tumor Immune Microenvironment and Genetic Signatures Identify Prognostic of LUAD

      00:00 - 00:00  |  Presenter: Si-Yang Liu

      • Abstract

      Loading...

    • +

      P72.03 - Tumor Microenvironment Disparity in Multiple Primary Lung Cancers

      00:00 - 00:00  |  Presenter: Motohiro Izumi

      • Abstract

      Loading...

    • +

      P72.04 - Statin Counteracts Cell Proliferation and EMT-Induction in NCI-H322M Cells Treated with TGF-β

      00:00 - 00:00  |  Presenter: Katsuhiko Warita

      • Abstract

      Loading...

    • +

      P72.05 - From OR to Lab: Optimized Protocol for Functional Immune Profiling of Freshly Resected Human Non-Small Cell Lung Carcinoma (NSCLC) Specimens

      00:00 - 00:00  |  Presenter: Sylvia Vania Alarcon

      • Abstract

      Loading...

    • +

      P72.06 - NLRP4-Mediated Type I Interferon Response Benefits Immune Checkpoint Therapy Through Redirecting CD8+ T Cell Distribution in TME

      00:00 - 00:00  |  Presenter: Liliang Xia

      • Abstract

      Loading...

    • +

      P72.07 - Modulation of the Tumor Microenvironment by Targeting ERb/HER Oncogenic Network in Lung Cancer Produces Synergy when Followed by Immunotherapy

      00:00 - 00:00  |  Presenter: Abdulaziz Abdullah Almotlak

      • Abstract

      Loading...

    • +

      P72.08 - Overexpression of LINC00942 is Associated With a Poor Prognosis and Immune Infiltration in    Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Jie Yang

      • Abstract

      Loading...

    • +

      P72.09 - Study of Relationship Between Proportion of CTLA-4 Positive Tregs in Tumor Infiltrating Lymphocytes and PD-L1 TPS

      00:00 - 00:00  |  Presenter: Satoshi Muto

      • Abstract

      Loading...

    • +

      P72.10 - Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Marie Vanderputten

      • Abstract

      Loading...

  • +

    P73 - Tumor Biology and Systems Biology - Basic and Translational Science - RTK/FGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology - Basic and Translational Science
    • +

      P73.01 - Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P73.02 - The Landscape of FGFR Alteration in Chinese Patients with Lung Cancer

      00:00 - 00:00  |  Presenter: Huilin Wang

      • Abstract

      Loading...

    • +

      P73.03 - A Kinome CRISPR Screen in FGFR-Amplified Lung Cancer

      00:00 - 00:00  |  Presenter: Zhang Yang

      • Abstract

      Loading...

  • +

    P74 - Health Services Research/Health Economics - Real World Evidence

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • +

      P74.01 - Barries in Precision Medicine Implementation Among Advanced Nonsquamous Cell Lung Cancer-Patients: A Real-World Scenario

      00:00 - 00:00  |  Presenter: Flavia Amaral Duarte

      • Abstract

      Loading...

    • +

      P74.02 - Treatment Patterns of EGFR mt+ NSCLC IV pts:  Real World Data of the NOWEL Network

      00:00 - 00:00  |  Presenter: Julia Roeper

      • Abstract

      Loading...

  • +

    P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P75.01 - Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

      00:00 - 00:00  |  Presenter: Toyoaki Hida

      • Abstract

      Loading...

    • +

      P75.02 - Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy

      00:00 - 00:00  |  Presenter: Haiyong Wang

      • Abstract

      Loading...

    • +

      P75.03 - KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Suman Rao

      • Abstract

      Loading...

    • +

      P75.04 - Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC

      00:00 - 00:00  |  Presenter: Petros Christopoulos

      • Abstract

      Loading...

    • +

      P75.05 - Integrative Modeling of Tumor Burden and Metastatic Pattern for Second-Line anti-PD-L1 Therapy of Non–Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Si-Cong Ma

      • Abstract

      Loading...

    • +

      P75.06 - Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases

      00:00 - 23:59  |  Presenter: Shinkichi Takamori

      • Abstract

      Loading...

    • +

      P75.07 - Association of FGFR4 Mutation With Immunotherapy Outcomes in Patients With Cancer

      00:00 - 00:00  |  Presenter: Lingshuang Liu

      • Abstract

      Loading...

    • +

      P75.08 - KDM5C Mutation Is Associated with Better Immunotherapy Outcomes in Non–Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Kun Wang

      • Abstract

      Loading...

    • +

      P75.09 - Analysis of Immune Microenvironment and Prognosis of NSCLC Patients Harbored SMARCA4 Mutation

      00:00 - 00:00  |  Presenter: Haiyong Wang

      • Abstract

      Loading...

    • +

      P75.10 - Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

      00:00 - 00:00  |  Presenter: Yiqing Huang

      • Abstract

      Loading...

    • +

      P75.11 - Potential Predictive Value of TERT Mutation Status for Response to Immunotherapy in Cancer Patients

      00:00 - 00:00  |  Presenter: Xiangyun Wang

      • Abstract

      Loading...

    • +

      P75.12 - Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy

      00:00 - 00:00  |  Presenter: Nitya Surya

      • Abstract

      Loading...

    • +

      P75.13 - Hyperprogressive Disease in Non-Small Cell Lung Cancer on pd-1 Inhibitor.

      00:00 - 00:00  |  Presenter: Tae-Won Jang

      • Abstract

      Loading...

    • +

      P75.14 - Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience 

      00:00 - 00:00  |  Presenter: Domenico Galetta

      • Abstract

      Loading...

    • +

      P75.15 - Predictive Factors of Survival in Non-Small Cell Lung Cancer Patients Without Durable Response to PD-1/L1 Inhibitors

      00:00 - 00:00  |  Presenter: Yuhei Harutani

      • Abstract

      Loading...

    • +

      P75.16 - Real-World Data from a Spanish Institution

      00:00 - 00:00  |  Presenter: Inmaculada Ramos

      • Abstract

      Loading...

    • +

      P75.17 - Baseline D-Dimer Levels Predict Prognosis in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

      00:00 - 00:00  |  Presenter: Jinliang Wang

      • Abstract

      Loading...

    • +

      P75.18 - Association of the LIPI With Survival and Response in Advanced NSCLC Patients Treated With Immune Checkpoint Inhibitors

      00:00 - 00:00  |  Presenter: Jinliang Wang

      • Abstract

      Loading...

    • +

      P75.19 - Investigation of Lung Cancer Patients Receiving Immunotherapy with Pre-Existing Lung Disease

      00:00 - 00:00  |  Presenter: Kerri McGovern

      • Abstract

      Loading...

    • +

      P75.20 - Outcomes of Lung Cancer Patients with Leptomeningeal Metastases Following Immune Checkpoint Inhibitor Treatments: A Pooled Analysis

      00:00 - 00:00  |  Presenter: meimei Zheng

      • Abstract

      Loading...

    • +

      P75.21 - Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study

      00:00 - 00:00  |  Presenter: Domenico Galetta

      • Abstract

      Loading...

    • +

      P75.22 - Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis

      00:00 - 00:00  |  Presenter: Kewei Ma

      • Abstract

      Loading...

  • +

    P76 - Targeted Therapy - Clinically Focused - EGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P76.01 - Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations

      00:00 - 00:00  |  Presenter: Yubo Wang

      • Abstract

      Loading...

    • +

      P76.02 - Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P76.03 - Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Enriqueta Felip

      • Abstract

      Loading...

    • +

      P76.04 - Prospective Study on Molecular Biomarkers in Advanced Lung Adenocarcinoma and Predilection for EGFR Mutation with Metastatic Sites

      00:00 - 00:00  |  Presenter: Mohanakrishnan Jayamani

      • Abstract

      Loading...

    • +

      P76.05 - Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis

      00:00 - 00:00  |  Presenter: David C. Qian

      • Abstract

      Loading...

    • +

      P76.06 - A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Dong Shen

      • Abstract

      Loading...

    • +

      P76.07 - Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus

      00:00 - 00:00  |  Presenter: Ruoshuang Han

      • Abstract

      Loading...

    • +

      P76.08 - High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs

      00:00 - 00:00  |  Presenter: Jia Liu

      • Abstract

      Loading...

    • +

      P76.09 - A Comparison of Sequential EGFR-TKI Therapy Versus First-Line Osimertinib in NSCLC: A Multi-Center, Retrospective Study

      00:00 - 00:00  |  Presenter: Chung-Shien Lee

      • Abstract

      Loading...

    • +

      P76.10 - Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study

      00:00 - 00:00  |  Presenter: Tianqing Chu

      • Abstract

      Loading...

    • +

      P76.11 - Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC

      00:00 - 00:00  |  Presenter: Sangtian Liu

      • Abstract

      Loading...

    • +

      P76.12 - Impact of Inflammatory Markers and Body Mass Index on TKI Toxicity in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation

      00:00 - 00:00  |  Presenter: Thanya Runciman

      • Abstract

      Loading...

    • +

      P76.13 - Osimertinib Delays but Not Prevents Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Jianjiao Ni

      • Abstract

      Loading...

    • +

      P76.14 - Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation

      00:00 - 00:00  |  Presenter: Nicholas Joseph Thomas

      • Abstract

      Loading...

    • +

      P76.15 - Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status

      00:00 - 00:00  |  Presenter: Jiyun Lee

      • Abstract

      Loading...

    • +

      P76.16 - EGFR-L858R NSCLC with Pleiotropic Resistance Mechanisms: T790M, C797S, SCLC-Transformation and KRAS, TP53, and BRAF Mutations.

      00:00 - 00:00  |  Presenter: Edyta Maria Urbanska

      • Abstract

      Loading...

    • +

      P76.17 - Prognostic Role of the Systemic Immune-Inflammatory Index (SII) in Driver-Mutation Positive NSCLC: Real-World EGFR-Mutant Disease

      00:00 - 00:00  |  Presenter: Amanda Jane Williams Gibson

      • Abstract

      Loading...

    • +

      P76.18 - Tissue- and Plasma-Based Landscape of Resistance to Osimertinib

      00:00 - 00:00  |  Presenter: Sun Min Lim

      • Abstract

      Loading...

    • +

      P76.19 - Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib

      00:00 - 00:00  |  Presenter: Chang Lu

      • Abstract

      Loading...

    • +

      P76.20 - The Predictive Values of Non-Resistant Nncommon EGFR Mutations in Advanced Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Peng-Bo Deng

      • Abstract

      Loading...

    • +

      P76.21 - EGFR-KDD with Duplication of Exons 18-26 Responding to Afatinib Treatment in a Patient with Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Yiying Qian

      • Abstract

      Loading...

    • +

      P76.22 - Acquired an EGFR Amplification in EGFR Exon 20 insertion Lung Adenocarcinoma Resistant to First Line Osimertinib Treatment

      00:00 - 00:00  |  Presenter: Chengwei Zhou

      • Abstract

      Loading...

    • +

      P76.23 - A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenter: SHO Mitsuya

      • Abstract

      Loading...

    • +

      P76.24 - A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P76.25 - Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKI and Once-Daily Thoracic RT: Predicting Values of Clinical and DVH Parameters

      00:00 - 00:00  |  Presenter: Xuexi Yang

      • Abstract

      Loading...

    • +

      P76.26 - Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy

      00:00 - 00:00  |  Presenter: Satvik Khaddar

      • Abstract

      Loading...

    • +

      P76.27 - ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

    • +

      P76.28 - Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC

      00:00 - 00:00  |  Presenter: Pingli Wang

      • Abstract

      Loading...

    • +

      P76.29 - Clinical Observation of EGFR-TKI Combined With 89Sr in the Treatment of Non-Small Cell Lung Cancer With Osteoblastic Reaction

      00:00 - 00:00  |  Presenter: Yu-ming Jia

      • Abstract

      Loading...

    • +

      P76.30 - The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC

      00:00 - 00:00  |  Presenter: Sherin Rouhani

      • Abstract

      Loading...

    • +

      P76.31 - Clinical Study of Apatinib Combined with Radiation Therapy in Advanced Non-small Cell Lung Cancer Patients with Brain Metastasis

      00:00 - 00:00  |  Presenter: Xiaqin Zhang

      • Abstract

      Loading...

    • +

      P76.32 - Real-World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation Treated with First and Second Generation TKI

      00:00 - 00:00  |  Presenter: Dalia Isabel Juarez

      • Abstract

      Loading...

    • +

      P76.33 - Concurrent EGFR and KRAS Mutations in Lung Adenocarcinoma: A Single Institution Case Series

      00:00 - 00:00  |  Presenter: Mahir Khan

      • Abstract

      Loading...

    • +

      P76.34 - Exosomal miRNAs Participate in Osimertinib Resistance Mainly Through Bypass Activation Mechanisms in Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Tangfeng Lv

      • Abstract

      Loading...

    • +

      P76.35 - Genomic Characristic and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Jiuwei Cui

      • Abstract

      Loading...

    • +

      P76.36 - A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Juan Li

      • Abstract

      Loading...

    • +

      P76.37 - Comprehensive Investigation of Uncommon EGFR Mutations in 14,429 Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Yuzhi An

      • Abstract

      Loading...

    • +

      P76.38 - Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S

      00:00 - 00:00  |  Presenter: Hongyun Zhao

      • Abstract

      Loading...

    • +

      P76.39 - Acquired Resistance Mechanisms in T790M-Positive Advanced NSCLC Tested by Non-Invasive Molecular Testing (NIMT) and Their Clinical Relevance

      00:00 - 00:00  |  Presenter: Piyakarn Watcharenwong

      • Abstract

      Loading...

    • +

      P76.40 - Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients.

      00:00 - 00:00  |  Presenter: Wenfeng Fang

      • Abstract

      Loading...

    • +

      P76.41 - Detection of Diverse EGFR c-terminal Truncations (C-trunc) and Sensitivity to Tyrosine Kinase Inhibitors (TKIs) in the Clinic

      00:00 - 00:00  |  Presenter: Christine M. Lovly

      • Abstract

      Loading...

    • +

      P76.42 - OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX

      00:00 - 00:00  |  Presenter: Josefa Terrasa

      • Abstract

      Loading...

    • +

      P76.44 - Application of Longitudinal Exposure-Response Modelling to Support Dacomitinib Starting Dose in Patients with EGFR Mutation-Positive NSCLC

      00:00 - 00:00  |  Presenter: Weiwei Tan

      • Abstract

      Loading...

    • +

      P76.45 - Evolution of Epidermal Growth Factor Receptor (EGFR) Gene Mutations in EGFR-TKIs Treated Chinese NSCLC

      00:00 - 00:00  |  Presenter: Xin Yu

      • Abstract

      Loading...

    • +

      P76.46 - First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer  

      00:00 - 00:00  |  Presenter: Wan-Ling Tan

      • Abstract

      Loading...

    • +

      P76.47 - Molecular Characteristics and Response to Diverse EGFR TKIs of NSCLC Patients Harboring EGFR E709-T710delinsX

      00:00 - 00:00  |  Presenter: Wenfeng Fang

      • Abstract

      Loading...

    • +

      P76.48 - A CT-Based Radiomic Feature Predicts EGFR Mutation and Response to Targeted Therapy in NSCLC

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P76.49 - The Impact of Baseline Systemic Inflammatory Status Parameters in Patients Treated with EGFR-Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenter: Petra Martin

      • Abstract

      Loading...

    • +

      P76.50 - Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure

      00:00 - 00:00  |  Presenter: Yu Feng

      • Abstract

      Loading...

    • +

      P76.51 - ERβ1 Expression Patterns have Different Effects on EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinoma.

      00:00 - 00:00  |  Presenter: Zhenxiang Li

      • Abstract

      Loading...

    • +

      P76.52 - Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC

      00:00 - 00:00  |  Presenter: Alessandro Leonetti

      • Abstract

      Loading...

    • +

      P76.53 - Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenter: Taihei Ono

      • Abstract

      Loading...

    • +

      P76.54 - Prognostic Value of Radiotherapy Pattern for Late-Stage Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinomas

      00:00 - 00:00  |  Presenter: Zhenxiang Li

      • Abstract

      Loading...

    • +

      P76.55 - Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC

      00:00 - 00:00  |  Presenter: Satoshi Igawa

      • Abstract

      Loading...

    • +

      P76.56 - High PD-L1 Expression is Aassociated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

      00:00 - 00:00  |  Presenter: Seung Hyeun Lee

      • Abstract

      Loading...

    • +

      P76.57 - Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond

      00:00 - 00:00  |  Presenter: Vered Fuchs

      • Abstract

      Loading...

    • +

      P76.58 - Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations

      00:00 - 00:00  |  Presenter: Haiyan Xu

      • Abstract

      Loading...

    • +

      P76.59 - Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations

      00:00 - 00:00  |  Presenter: Baohui Han

      • Abstract

      Loading...

    • +

      P76.60 - FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation

      00:00 - 00:00  |  Presenter: Qing Zhou

      • Abstract

      Loading...

    • +

      P76.61 - Long Follow up Study of Comparing Erlotinib (ER) with Gefitinib (GE) for Previously Treated Advanced Non-Small Cell Lung Cancer: WJOG5108LFS

      00:00 - 00:00  |  Presenter: Ryo Toyozawa

      • Abstract

      Loading...

    • +

      P76.62 - RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

      00:00 - 00:00  |  Presenter: Andreas N Saltos

      • Abstract

      Loading...

    • +

      P76.63 - Dacomitinib Induces a Drastic Response in Metastatic Brain Lesions of Patients with EGFR-mutant Non-small-cell Lung Cancer: A Brief Report

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P76.64 - Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)

      00:00 - 00:00  |  Presenter: Benjamin Solomon

      • Abstract

      Loading...

    • +

      P76.65 - CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a Phase I-II Dose-Expansion Study

      00:00 - 00:00  |  Presenter: Yuankai Shi

      • Abstract

      Loading...

    • +

      P76.66 - Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC

      00:00 - 00:00  |  Presenter: Jorge Nieva

      • Abstract

      Loading...

    • +

      P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050

      00:00 - 00:00  |  Presenter: Adam Pluzanski

      • Abstract

      Loading...

    • +

      P76.68 - The Impact of Eligibility for Anti-Angiogenic Treatment to the Prognosis of Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

      00:00 - 00:00  |  Presenter: Hiroaki Kodama

      • Abstract

      Loading...

    • +

      P76.69 - Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US

      00:00 - 00:00  |  Presenter: Lauren Bartolome

      • Abstract

      Loading...

    • +

      P76.70 - Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Jacqueline V. Aredo

      • Abstract

      Loading...

    • +

      P76.71 - RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations

      00:00 - 00:00  |  Presenter: Shuta Ohara

      • Abstract

      Loading...

    • +

      P76.72 - A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases

      00:00 - 00:00  |  Presenter: Simon Ekman

      • Abstract

      Loading...

    • +

      P76.73 - MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

      00:00 - 00:00  |  Presenter: S. Martin Shreeve

      • Abstract

      Loading...

    • +

      P76.74 - PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

      00:00 - 00:00  |  Presenter: Trishala Agrawal

      • Abstract

      Loading...

    • +

      P76.75 - Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Kiran Munawar

      • Abstract

      Loading...

    • +

      P76.76 - EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin

      00:00 - 00:00  |  Presenter: Élia Rodrigues Cipriano

      • Abstract

      Loading...

    • +

      P76.77 - Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations

      00:00 - 00:00  |  Presenter: Weineng Feng

      • Abstract

      Loading...

    • +

      P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study

      00:00 - 00:00  |  Presenter: Qing Zhou

      • Abstract

      Loading...

    • +

      P76.79 - Osimertinib in Poor PS Patients with T790M-Positive Advanced NSCLC after Progression of EGFR TKI Treatments (NEJ032B)

      00:00 - 00:00  |  Presenter: Ryota Saito

      • Abstract

      Loading...

    • +

      P76.80 - The Role of Surgical Resection of Advanced Non-Small Cell Lung Cancer after a Response to EGFR-TKI

      00:00 - 00:00  |  Presenter: Po-Lan Su

      • Abstract

      Loading...

    • +

      P76.81 - Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR–RAD51 Fusion: A Brief Report

      00:00 - 00:00  |  Presenter: Han-Min Wang

      • Abstract

      Loading...

    • +

      P76.82 - Osimertinib versus First-Generation EGFR-TKIs in Untreated EGFR-Mutant NSCLC with Brain Metastasis: 362 Real-World Cases

      00:00 - 00:00  |  Presenter: Jianjiao Ni

      • Abstract

      Loading...

    • +

      P76.83 - Brain Metastasis from Lung Cancers - Intermittent High Dose Afatinib as a Palliative Salvage Therapy for EGFR+ NSCLC.

      00:00 - 00:00  |  Presenter: Jo Monsen

      • Abstract

      Loading...

    • +

      P76.84 - EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

      00:00 - 00:00  |  Presenter: Maisha T Chowdhury

      • Abstract

      Loading...

    • +

      P76.85 - Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenter: Sukhmani K. Padda

      • Abstract

      Loading...

    • +

      P76.87 - Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases

      00:00 - 00:00  |  Presenter: Daniel Chan

      • Abstract

      Loading...

    • +

      P76.88 - Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs

      00:00 - 00:00  |  Presenter: Jun Ma

      • Abstract

      Loading...

    • +

      P76.89 - Is it Possible to Halt Cachexia in Poor Performance Patients with Metastatic EGFR Positive Lung Cancer?

      00:00 - 00:00  |  Presenter: Zhuang Yao Boh

      • Abstract

      Loading...

    • +

      P76.90 - Molecular Characteristics of BRAF Mutations in EGFR Mutant NSCLC after Progression on EGFR TKIs and Response to Combination Targeted Therapy

      00:00 - 00:00  |  Presenter: Wenfeng Fang

      • Abstract

      Loading...

    • +

      P76.91 - Analysis of P53 Lysine-Encoding Mutations Reveals a Relationship Between Codon 132 Mutations and EGFR Mutations in Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Jing Zhang

      • Abstract

      Loading...

    • +

      P76.92 - TKI and Intrathoracic Perfusion in First-line Stage IV Lung Adenocarcinoma with EGFR Mutation and Malignant Pleural Effusion

      00:00 - 00:00  |  Presenter: Weijia Huang

      • Abstract

      Loading...

    • +

      P76.93 - The Efficacy of Second-Line Osimertinib  Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

    • +

      P76.94 - Survival Analyses and Molecular Predictors of Outcomes in Patients Treated with Osimertinib for Metastatic NSCLC Harboring EGFR Mutation

      00:00 - 00:00  |  Presenter: Danilo Giffoni M. M. Mata

      • Abstract

      Loading...

    • +

      P76.95 - Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Kai-Cheng Peng

      • Abstract

      Loading...

    • +

      P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC

      00:00 - 00:00  |  Presenter: Jianying Zhou

      • Abstract

      Loading...

    • +

      P76.97 - Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis

      00:00 - 00:00  |  Presenter: DEZHI Cheng

      • Abstract

      Loading...

    • +

      P76.98 - NSCLC Patients With Rare EGFR Mutations in Exons 18 and 19 Benefits From Treatment With EGFR Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenter: Junying Xu

      • Abstract

      Loading...

    • +

      P76.99 - Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

      00:00 - 00:00  |  Presenter: Dongqing Lv

      • Abstract

      Loading...

    • +

      P76.100 - Primary Drug Resistance to EGFR-TKIs by EGFR p.V1010M Germline Mutation Combined with EGFR p.L858R Somatic Mutation and its Pedigree Analysis

      00:00 - 00:00  |  Presenter: Youfan Jiang

      • Abstract

      Loading...

  • +

    P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P77.01 - Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC

      00:00 - 00:00  |  Presenter: John Wrangle

      • Abstract

      Loading...

    • +

      P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

    • +

      P77.03 - A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

      00:00 - 00:00  |  Presenter: David R. Spigel

      • Abstract

      Loading...

    • +

      P77.05 - Phase II Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC After Progression on First-Line Therapy: BTCRC-LUN15-017

      00:00 - 00:00  |  Presenter: Emily Sisel

      • Abstract

      Loading...

  • +

    P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P78.01 - Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057

      00:00 - 00:00  |  Presenter: Sanjay Popat

      • Abstract

      Loading...

    • +

      P78.02 - A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non–Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Chang Liu

      • Abstract

      Loading...

    • +

      P78.03 - Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC

      00:00 - 00:00  |  Presenter: Cheng Huang

      • Abstract

      Loading...

    • +

      P78.04 - Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients With Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Kazutoshi Komiya

      • Abstract

      Loading...

    • +

      P78.05 - Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome

      00:00 - 00:00  |  Presenter: Cameron Champion Wood

      • Abstract

      Loading...

    • +

      P78.06 - Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch)

      00:00 - 00:00  |  Presenter: Tomoya Fukui

      • Abstract

      Loading...

    • +

      P78.07 - High Grade Toxicity and Response to PD-1 Axis Inhibitors in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Mor Moskovitz

      • Abstract

      Loading...

    • +

      P78.08 - Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland

      00:00 - 00:00  |  Presenter: Magdalena Knetki-Wróblewska

      • Abstract

      Loading...

    • +

      P78.09 - Immunotherapy Beyond Progression for Patients with Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Jinliang Wang

      • Abstract

      Loading...

    • +

      P78.10 - Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression and Coexistent  RET- Fusion: The Description of Two Cases.

      00:00 - 00:00  |  Presenter: Magdalena Knetki-Wróblewska

      • Abstract

      Loading...

    • +

      P78.11 - Immunotherapy-Induced Coeliac Disease in the Curative Lung Cancer Patient on Adjuvant Durvalumab 

      00:00 - 00:00  |  Presenter: Samantha Rae Hopkins (Maiden Name Kestenbaum)

      • Abstract

      Loading...

    • +

      P78.12 - A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer

      00:00 - 00:00  |  Presenter: Domenico Galetta

      • Abstract

      Loading...

    • +

      P78.13 - Real-World Outcomes After Immunotherapy in NSCLCa: The Experience of the Oncology Center of Hospital Moinhos De Vento.

      00:00 - 00:00  |  Presenter: Fernando Castilho Venero

      • Abstract

      Loading...

    • +

      P78.14 - The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan

      00:00 - 00:00  |  Presenter: Yuriko Yagi

      • Abstract

      Loading...

    • +

      P78.15 - Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy

      00:00 - 00:00  |  Presenter: Cristina Julian

      • Abstract

      Loading...

    • +

      P78.16 - Real-World Outcomes of Camrelizumab (SHR-1210) in Treating Advanced Non-Small Cell Lung Cancer: A Multicenter Prospective Study

      00:00 - 00:00  |  Presenter: Kangsheng Gu

      • Abstract

      Loading...